个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making (Open Access)

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Si-Ye Chen[1] * ; Yong Yang[1] * ; Shu-Nan Qi[1] * ; Ying Wang[2] ; Chen Hu[3] ; Xia He[4] ; Li-Ling Zhang[5] ; Gang Wu[5] ; Bao-Lin Qu[6] ; Li-Ting Qian[7] ; Xiao-Rong Hou[8] ; Fu-Quan Zhang[8] ; Xue-Ying Qiao[9] ; Hua Wang[10] ; Gao-Feng Li[11] ; Yu-Jing Zhang[12] ; Yuan Zhu[13] ; Jian-Zhong Cao[14] ; Sheng-Min Lan[14] ; Jun-Xin Wu[15] ; Tao Wu[16] ; Su-Yu Zhu[17] ; Mei Shi[18] ; Li-Ming Xu [19] ; Zhi-Yong Yuan[19] ; Joachim Yahalom[20] ; Richard Tsang[21] ; Yu-Qin Song[22] ; Jun Zhu[22] ; Hang Su[23] ; Ye-Xiong Li[1] ;
机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, PR China [2]Chongqing University Cancer Hospital & Chongqing Cancer Hospital, Chongqing, PR China [3]Division of Biostatistics and Bioinformatics, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2013, USA [4]Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, PR China [5]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China [6]The General Hospital of Chinese People’s Liberation Army, Beijing, PR China [7]The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, PR China [8]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, PR China [9]The Fourth Hospital of Hebei Medical University, Shijiazhuang, PR China [10]The Second Affiliated Hospital of Nanchang University, Nanchang, PR China [11]Beijing Hospital, National Geriatric Medical Center, Beijing, PR China [12]State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center [13]Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China [14]Zhejiang Cancer Hospital, Hangzhou, Zhejiang, PR China [15]Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, Shanxi, PR China [16]Fujian Provincial Cancer Hospital, Fuzhou, Fujian, PR China [17]Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, Guizhou, PR China [18]Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, PR China [19]Xijing Hospital of Fourth Military Medical University, Xi’an, PR China [20]Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, PR China [21]Memorial Sloan Kettering Cancer Center, New York, NY, USA [22]Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada [23]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, PR China [24]The Fifth Medical Center of PLA General Hospital, Beijing, PR China
出处：
DOI： 10.1038/s41375-020-0791-3
ISSN：

摘要：
Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL) who were mostly treated with anthracycline-based chemotherapy, we propose an easily used nomogram-revised risk index (NRI), validated it and compared with Ann Arbor staging, the International Prognostic Index (IPI), Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) for overall survival (OS) prediction by examining calibration, discrimination, and decision curve analysis in a validation cohort of 1582 patients primarily treated with non-anthracycline-based chemotherapy. The calibration of the NRI showed satisfactory for predicting 3- and 5-year OS in the validation cohort. The Harrell’s C-index and integrated Brier score (IBS) of the NRI for OS prediction demonstrated a better performance than that of the Ann Arbor staging system, IPI, KPI, and PINK. Decision curve analysis of the NRI also showed a superior outcome. The NRI is a promising tool for stratifying patients with ENKTCL into risk groups for designing clinical trials and for selecting appropriate individualized treatment. © 2020, The Author(s).

基金：
Funding This work was supported by grants from the Chinese Academy of Medical Science (CAMS) Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1–001) and the National Key Projects of Research and Development of China (2016YFC0904600).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 2 区 血液学 2 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 血液学 2 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 HEMATOLOGY Q1 ONCOLOGY
最新[2024]版：
Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, PR China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Si-Ye Chen,Yong Yang,Shu-Nan Qi,et al.Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making (Open Access)[J].LEUKEMIA.2021,35(1):130-142.doi:10.1038/s41375-020-0791-3.
APA：
Si-Ye Chen,Yong Yang,Shu-Nan Qi,Ying Wang,Chen Hu...&Ye-Xiong Li.(2021).Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making (Open Access).LEUKEMIA,35,(1)
MLA：
Si-Ye Chen,et al."Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making (Open Access)".LEUKEMIA 35..1(2021):130-142

资源点击量：42313 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号